Healthstock project falls within the livestock feed market. The main problem that feedstock industry faces nowadays is that animals are so forced to grow that they have develop disproportionately big digestive systems to be capable to process the fodder. These overdeveloped organs are at the same time under-protected systems, more vulnerable to digestive diseases.
This deficit is counterbalanced by an extensive use of preventive drugs and antibiotics. Consequently, the animals suffer more, the producers spend more, the butchers obtain less and the consumer pays more for lower-quality drug-treated food thanks to this counter-nature situation.
In this framework, a big market opportunity appears for feed improvers. These products are mixed with the traditional feeding, improving animal health and by extension reducing the incidence of diseases.
Currently, there are two types of improvers in the market that complement the common animal feed and improve the digestibility of the feed producing benefits over the organism of the animal:
• Probiotics (based on living bacteria):
They have dominated the European market, with high potential activity but identified as additives by regulation (expensive trials are needed to demonstrate no negative impact) and with highly variable effectiveness due to stability drawbacks in storage.
• Fermented prebiotics(based on dead bacteria):
They have dominated the North American market. They don’t have the living bacteria drawbacks, however, they have less effectiveness than probiotics
PENTABIOL has developed and tested PROBISAN, a postbiotic improver (both probiotic and prebiotic effects) that overtakes the performance of any other animal feed improver in the market.
PROBISAN, is the product resulting from the fermentation process of a joint culture of lactic acid bacteria and yeasts.
Due to its behavior similar to those of a joint probiotic and prebiotic action, it greatly favors animal health, achieving the dual objective of enhancing the productive results of farms and reducing the application of medicines progressively.
The resulting microorganisms are linked to a plant substrate. After the intake of this substrate, it is when the action of the microorganisms in the digestive system begins, which is carried out in the form of metabolites (among others, organic acids such as lactic and acetic acid, and various vitamins of group B). These metabolites are generated during the successive liquid and solid, aerobic and anaerobic fermentations to which the product is subjected, which are able to inactivate by drying the initiating microorganisms in the last solid fermentation.
Its uniqueness, compared to similar products lies in its high efficiency determined by the fermentation process, since the set of microorganisms it contains, in addition to the positive effect on the metabolism, encourage the installation and growth of the microflora in the digestive tract of animals, regulating and stabilizing the conditions of digestion.
Its presentation and registration is in accordance with the current Regulation (EU) No. 68/2013 of the commission of January 16, 2013 on the catalog of raw materials for animal feed, in Glossary of treatments, point 28, where it details that fermented feed is the procedure in which microorganisms such as bacteria, fungi or yeasts are produced or used to act on the materials in order to promote a change in their composition / chemical properties.
The overall objective of HEAKTHSOCK project is the INTRODUCTION OF PROBISAN IN THE MAIN GLOBAL REFERENCE MARKETS OF LIVESTOCK FEEDING.
As a part of the commercialisation plan to introduce and commercialise PROBISAN worldwide, this project aims to introduce PROBISAN in the global reference markets which will boost the introduction in the rest of the markets in a later stage of commercialisation after this project.
According to the commercialisation plan, the specific objectives and the work performed to achieve each one of them have been the following:
Objetive 1: Product
1.1 Product range development
Objetive 2: Promotion
2.1 Demonstration of effectiveness in the main global reference markets (Spain, Italy, Germany, Peru, United States, Morocco and China)
2.2 Communication and dissemination of the demonstration results among stakeholders
Objetive 3: Distribution
